# Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage

> **NCT04252248** · PHASE1 · TERMINATED · sponsor: **University Hospital Heidelberg** · enrollment: 3 (actual)

## Conditions studied

- Head and Neck Cancer
- Anogenital Cancer

## Interventions

- **DRUG:** Dacogen

## Key facts

- **NCT ID:** NCT04252248
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-11
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-06-15
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Organizational reasons
- **Last updated:** 2021-10-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252248, "Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04252248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*